When Fernando Goldsztein was told nothing could save his 9-year-old son from a deadly brain tumor, he made a decision that would change pediatric cancer treatment forever. Today, his relentless pursuit has created breakthrough treatments that are giving hope to thousands of children facing similar death sentences.
“Kids with brain tumors were left behind. Because the treatments are very old, they are from the 80s, believe it or not,” Goldsztein told Fox News in a recent interview.
Goldsztein’s son Frederico was diagnosed with medulloblastoma, the most common childhood brain tumor, at just nine years old. Despite its relative frequency among brain cancers, medulloblastoma remains rare – affecting only five out of every million children annually. This rarity has historically made research funding difficult to secure, leaving treatment protocols virtually unchanged for decades.
The family’s nightmare deepened when Frederico’s cancer returned after initial treatment.
“I was told by the doctors back then that there was nothing to do to save my son, that I should go back home and spend time with him,” Goldsztein recalled, his voice reflecting the devastation any parent would feel facing such news.
GRIM STATISTICS HIDE HEARTBREAKING REALITY
While standard medulloblastoma has a relatively promising 80% five-year survival rate with conventional treatments, the odds plummet dramatically when the disease returns. Recurrent medulloblastoma drops to a grim 40% survival rate – a statistic that hasn’t improved in decades due to minimal research investment.
St. Jude’s Children’s Hospital estimates around 400,000 children worldwide will be diagnosed with cancer this year alone. Though American children have seen improved survival rates for many cancers, certain types – particularly rare brain tumors – have seen minimal progress.
For most parents, such a diagnosis would mean accepting the inevitable and treasuring final moments. Goldsztein, however, wasn’t willing to surrender his son without a fight.
“When I received that devastating news five years ago, after two weeks, I kind of recovered – you never recover, right? But I kind of recovered and I said, ‘I’ve got to do something, I will do something,'” he explained.
FROM DESPERATE FATHER TO MEDICAL REVOLUTIONARY
Two years after his son’s cancer returned, Goldsztein launched the Medulloblastoma Initiative (MBI) alongside Dr. Roger Packer, one of the world’s leading medulloblastoma researchers at Children’s National Hospital in Washington, D.C.
Unlike traditional research models that often work in isolation, MBI created something revolutionary – a collaborative network forcing the best scientific minds to work together rather than compete.
“We are trying to find a cure for this disease as soon as possible. So, it’s a model that brings together the best minds in the field,” Goldsztein explained. “MBI is all about collaboration and synergy. The scientists, to be funded by us, they have to work as a group.”
This radical approach has unified more than a dozen laboratories worldwide, creating unprecedented synergy in a field typically fragmented by competition for limited funding.
“By each one having each piece of the puzzle, we were able to move very fast and are achieving very interesting results,” he said.
BREAKTHROUGH TREATMENTS EMERGE FROM FATHER’S MISSION
The results speak for themselves. Since Fox last interviewed the MBI team, the initiative has successfully fast-tracked at least two FDA-approved clinical trials at the University of Florida specifically targeting medulloblastoma, with several other promising studies in development.
“We have much more in our pipeline,” Goldsztein said. “We are excited with these results.”
In one groundbreaking clinical trial funded by MBI, scientists are reprogramming patients’ white blood cells to seek and destroy tumor cells – essentially creating a living medicine that hunts cancer. Early results have been nothing short of miraculous, with one participant’s aggressive tumor nearly eliminated completely.
A separate study, still in the animal testing phase, is investigating an experimental mRNA-based cancer vaccine – similar technology to what revolutionized COVID-19 prevention. This innovative approach could lead to a universal shot that supercharges a patient’s immune system against brain tumors.
For children battling the deadliest forms of brain cancer, these developments represent more than scientific advancement – they offer precious hope where none existed before.
FATHER AND SON RACE AGAINST TIME
The most remarkable aspect of the MBI model is its efficiency. Unlike traditional research pathways that can take decades to move from lab to patient, Goldsztein’s initiative has compressed the timeline dramatically.
“We’ve already managed to get two clinical trials approved by the FDA in the United States in record time — an unprecedented achievement,” he noted in a recent interview.
This urgency stems directly from Goldsztein’s personal stake. His son Frederico continues battling recurrent medulloblastoma at age 18, making the family’s quest quite literally a matter of life and death.
“He is an outlier, but we know that this type of tumor comes back, so it’s running against time. And that’s why we are moving fast to save him and to save thousands of other kids out there,” Goldsztein said.
Frederico’s continued survival defies medical expectations, likely due in part to innovative treatments developed through his father’s initiative. While his prognosis remains uncertain, every day represents a victory against a disease that typically claims young lives within months of recurrence.
AMERICA’S MEDICAL INNOVATION LEADS THE WAY
The groundbreaking work being conducted through American research institutions exemplifies why the U.S. healthcare system, despite its challenges, remains the global leader in medical innovation.
Dr. Roger Packer, who partnered with Goldsztein to launch MBI, has devoted his career to advancing pediatric brain tumor treatment at Children’s National Hospital. His expertise, combined with the collaborative model established through MBI, has created a pipeline for treatments that would likely never have materialized through traditional research channels.
Notably, the initiative emphasizes fiscal responsibility alongside scientific excellence. “100% of the donations given to MBI go to supporting research and clinical trials to help kids like Frederico,” Goldsztein emphasized, ensuring every dollar contributes directly to finding a cure.
A FATHER’S DETERMINATION CHANGES MEDICAL HISTORY
The story of Fernando and Frederico Goldsztein transcends typical medical narratives. It represents the quintessentially American spirit of refusing to accept limitations, even when delivered by the highest authorities.
When told nothing could save his son, Goldsztein didn’t simply seek second opinions or alternative treatments – he created an entirely new research model that is reshaping how rare pediatric cancers are studied and treated.
“This is how innovation happens,” explains Dr. Michael Werner, oncology specialist at Memorial Sloan Kettering Cancer Center, who is not affiliated with MBI but has followed their progress. “Sometimes it takes someone outside the traditional system to challenge conventions and create breakthroughs.”
As Frederico continues defying the odds against a disease that has claimed countless young lives, his father’s initiative offers hope to families worldwide facing similar diagnoses.
“I believe this model could transform treatment for many rare pediatric diseases,” Goldsztein said. “When conventional wisdom says ‘impossible,’ that’s precisely when we need to push hardest for solutions.”
THE FUTURE OF BRAIN CANCER TREATMENT
Scientists involved with MBI predict their collaborative approach could reduce research timelines by years, potentially saving thousands of lives that would otherwise be lost waiting for treatments to navigate traditional development pipelines.
Recent breakthroughs at institutions like SickKids Hospital and the University of Toronto have identified critical molecular vulnerabilities in medulloblastoma cells – discoveries that are now being rapidly incorporated into MBI’s treatment strategies.
“We’re seeing unprecedented cross-pollination of ideas,” explained Dr. Packer. “Discoveries made in Toronto are immediately shared with teams in Florida and Washington, creating exponential progress impossible under traditional research models.”
The initiative’s success demonstrates how private philanthropy can accelerate medical research when strategically deployed. By eliminating bureaucratic barriers and fostering true collaboration, MBI has compressed what would typically be decades of research into just a few years.
For children diagnosed with brain tumors today, this acceleration could mean the difference between life and death.
HOPE FOR THOUSANDS OF AMERICAN FAMILIES
Approximately 4,000 American children are diagnosed with brain tumors annually, with medulloblastoma representing one of the most common and devastating forms. For decades, these families have faced treatment protocols with minimal improvement since the 1980s.
MBI’s work promises to change that narrative dramatically.
“We’re no longer just extending life by months – we’re pursuing actual cures,” Goldsztein explained. “These children deserve more than temporary remissions; they deserve the chance to grow up.”
As clinical trials continue showing promising results, the initiative is expanding its focus to additional rare pediatric brain cancers, potentially impacting thousands more families facing devastating diagnoses.
The Goldszteins’ journey from personal tragedy to medical revolution offers a powerful reminder that determination can sometimes accomplish what science alone cannot.
Chicago Residents Demand More Police as Violent Crime Terrorizes Neighborhoods
FAQ SECTION
Q: What is medulloblastoma and how common is it?
A: Medulloblastoma is the most common malignant brain tumor in children, though still rare – affecting only 5 out of 1 million children annually. It typically forms in the cerebellum, the part of the brain controlling movement and coordination.
Q: What is the survival rate for children with medulloblastoma?
A: The five-year survival rate for standard medulloblastoma is approximately 80% with conventional treatment. However, when the disease returns (recurrent medulloblastoma), the survival rate drops dramatically to less than 40%.
Q: What makes the Medulloblastoma Initiative different from other research organizations?
A: MBI requires all funded scientists to collaborate rather than compete, pooling resources and knowledge across international research centers. This approach has accelerated breakthroughs and clinical trials that would typically take decades under traditional research models.
Q: How can I support the fight against childhood brain cancer?
A: You can donate directly to the Medulloblastoma Initiative at mbinitiative.org, where 100% of contributions fund research and clinical trials. Spreading awareness about pediatric brain cancer also helps drive additional support and funding.
Q: Are the new treatments mentioned in this article available to all children with medulloblastoma?
A: Currently, some treatments are available through clinical trials with specific eligibility requirements. Families should consult with their pediatric oncologists about potential trial participation and emerging treatment options.
CTA: Join the fight against childhood brain cancer by supporting breakthrough research at mbinitiative.org today.
Copyright © Stucci Media 2025 | All Rights Reserved
